^
Association details:
| Biomarker: | STK11 mutation + KRAS mutation + TP53 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
Published date:
03/15/2022
Excerpt:
...introduction of a Stk11/Lkb1 (L) mutation into murine lung adenocarcinomas driven by mutant Kras and Trp53 loss (KP) resulted in an ICB refractory syngeneic KPL tumor....we treated C57BL/6J mice bearing KPL tumors with the selective Axl kinase inhibitor bemcentinib (BGB324) alone, anti-PD-1 alone, or with a combination of anti-PD-1 + BGB324. Although neither treatment alone controlled tumor growth, the combination of BGB324 with anti-PD-1 showed sustained control of tumor progression...
Secondary therapy:
PD1 inhibitor
DOI:
https://doi.org/10.1016/j.xcrm.2022.100554
